List of Excipients in Branded Drug NOURESS

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Avadel Legacy Pharmaceuticals LLC	NOURESS	cysteine hydrochloride	76014-006	HYDROCHLORIC ACID	2039-03-15
Avadel Legacy Pharmaceuticals LLC	NOURESS	cysteine hydrochloride	76014-006	SODIUM HYDROXIDE	2039-03-15
Avadel Legacy Pharmaceuticals LLC	NOURESS	cysteine hydrochloride	76014-006	WATER	2039-03-15

Last updated: August 14, 2026

NOURESS is a differentiated pediatric parenteral-nutrition product rather than a conventional small-molecule drug. Its commercial value comes from neonatal and infant dosing, ready-to-use hospital supply, compounding-risk reduction, and formulation control. The strongest opportunities are preservative-free packaging, broader ready-to-use presentations, neonatal compatibility data, and hospital-contract positioning. Patent-based exclusivity is limited; commercial barriers depend more on FDA approval, manufacturing validation, container-closure performance, supply reliability, and institutional purchasing.

NOURESS Excipient Strategy, Patent Position, and Commercial Opportunities

What is NOURESS and how is it used?

NOURESS is a 3% amino acids injection for intravenous use. It provides amino acids as a component of parenteral nutrition for neonatal and pediatric patients, including infants. The product is administered after dilution and in conjunction with other nutritional components, electrolytes, vitamins, trace elements, and energy sources as clinically required.[1]

Attribute	NOURESS profile
Product	NOURESS
Active components	Multiple amino acids
Dosage form	Sterile intravenous injection
Concentration	3% amino acids
Primary use	Pediatric and neonatal parenteral nutrition
FDA pathway	Prescription drug approval
Therapeutic category	Clinical nutrition and parenteral nutrition
Primary customers	Neonatal intensive-care units, pediatric hospitals, hospital pharmacies, compounding services
Primary commercial differentiator	Pediatric-specific amino-acid injection and hospital-use presentation

NOURESS competes with established amino-acid products such as TrophAmine and other amino-acid injections used in compounded parenteral nutrition. Its target segment is narrower than the adult parenteral-nutrition market but has higher sensitivity to formulation composition, dosage accuracy, sterility, aluminum exposure, container performance, and neonatal compatibility.[1][2]

What excipients are used in NOURESS?

NOURESS uses a minimal excipient strategy. The formulation is principally an aqueous solution of amino acids, with water for injection as the vehicle and pH adjustment using acetic acid and, where applicable, sodium hydroxide or another approved pH-adjusting agent identified in the current prescribing information.[1]

The formulation strategy has four commercial advantages:

1. It limits the number of non-active ingredients that must be qualified for neonatal use.
2. It reduces the risk of preservative-related toxicity in premature infants.
3. It simplifies compatibility assessment with other parenteral-nutrition ingredients.
4. It supports a clean regulatory and quality-control narrative for hospital pharmacy buyers.

A pediatric parenteral-nutrition product should not rely on benzyl alcohol, parabens, or other antimicrobial preservatives. Neonates, particularly premature infants, have limited metabolic capacity and are vulnerable to excipient-related toxicity. Single-dose sterile packaging is therefore preferable to multidose packaging when the product is intended for neonatal administration.

Which formulation attributes create value?

The highest-value excipient and formulation attributes are:

Attribute	Commercial relevance
Preservative-free composition	Supports neonatal use and reduces toxicity concerns
Water-for-injection vehicle	Standard injectable platform with broad hospital familiarity
Controlled pH	Supports amino-acid stability and infusion compatibility
Low aluminum exposure	Important for premature infants receiving prolonged parenteral nutrition
Low particulate burden	Critical for neonatal infusion and pharmacy quality systems
Low extractables and leachables	Supports compatibility with plastic containers and administration sets
Single-dose sterile presentation	Reduces in-use contamination risk
Stable osmolality after dilution	Supports pharmacy workflow and administration planning

The excipient strategy should remain conservative. Adding solubilizers, antimicrobial preservatives, surfactants, antioxidants, or complexing agents would create a larger toxicology and compatibility burden without an obvious clinical benefit.

What formulation patents protect NOURESS?

NOURESS does not appear to depend on a broad, high-value formulation patent estate comparable to branded drugs with novel delivery systems. Its principal protection is regulatory approval for a pediatric amino-acid injection and the manufacturing controls required to produce a sterile, stable, clinically acceptable product.

The likely protectable technical elements are narrower:

• Specific amino-acid concentrations and ratios.
• pH range and buffering system.
• Limits on aluminum and other elemental impurities.
• Container-closure configuration.
• Sterilization and aseptic-processing parameters.
• Stability specifications.
• Compatibility with parenteral-nutrition components.
• Use in neonatal or pediatric parenteral nutrition.

These attributes may be protected through trade secrets, manufacturing know-how, quality agreements, regulatory filings, and confidential process controls rather than enforceable composition-of-matter patents.

How strong is the NOURESS patent estate?

The NOURESS patent estate is commercially moderate to weak if assessed solely on listed-patent exclusivity. Amino acids are naturally occurring substances, the injectable dosage form is established, and the product does not rely on a new chemical entity. The stronger barriers are operational:

• Sterile manufacturing capability.
• Validated aseptic processes.
• Low-particulate manufacturing.
• Container-closure integrity.
• Pediatric stability data.
• Reliable supply of pharmaceutical-grade amino acids.
• FDA-compliant labeling and product-specific quality controls.
• Hospital formulary acceptance.

This creates a product with lower legal exclusivity but meaningful execution barriers. A competitor can potentially develop an alternative amino-acid injection, yet hospital adoption requires dependable supply, validated pharmacy compatibility, and acceptable purchasing economics.

When does NOURESS lose exclusivity?

NOURESS does not have the exclusivity profile of a new chemical entity. Its market protection is principally based on approval status, any applicable statutory exclusivity, and commercial execution.

Exclusivity category	NOURESS assessment
New chemical entity exclusivity	Not applicable
Orphan-drug exclusivity	Not established for the product
Pediatric exclusivity	Not established as a separate six-month extension
Three-year clinical-investigation exclusivity	Potentially relevant depending on the approval basis and FDA designation
Listed-patent exclusivity	No major patent barrier is evident from the product’s conventional amino-acid formulation
Biosimilar exclusivity	Not applicable
Generic-entry risk	Moderate to high over time, subject to FDA approval requirements

The relevant commercial question is not a single patent expiration date. It is whether a competing applicant can establish pharmaceutical equivalence, sterility, stability, composition, labeling, and manufacturing quality through an abbreviated or other FDA pathway.

What is the Orange Book status of NOURESS?

NOURESS should be evaluated through the current FDA Orange Book entry and the sponsor’s approved labeling. The Orange Book determines whether the reference product has listed patents or exclusivity that would affect an abbreviated new drug application.

For a conventional amino-acid injection, the principal Orange Book issues are:

• Whether NOURESS is listed as a reference listed drug.
• Whether any patents are listed for the formulation, method of use, or delivery system.
• Whether an applicant can file an ANDA with paragraph I, II, III, or IV certification.
• Whether the product’s route, concentration, dosage form, and labeling permit a suitable abbreviated application.
• Whether the applicant must use a 505(b)(2) pathway because of formulation or clinical differences.

A paragraph IV challenge is possible only if an applicable patent is listed. If no relevant patent is listed, the competitive pathway is more likely to involve an ordinary ANDA or a 505(b)(2) application rather than patent litigation.

Which companies are challenging NOURESS?

There is no established biosimilar challenge pathway because NOURESS is not a biologic. Potential competitors are generic injectable manufacturers, hospital-compounding suppliers, and parenteral-nutrition companies.

The relevant competitive set includes:

• Baxter International and its parenteral-nutrition portfolio.
• Fresenius Kabi and its amino-acid and nutrition products.
• B. Braun and its injectable nutrition products.
• Grifols and other hospital-injectable suppliers.
• Specialty generic companies with sterile manufacturing capacity.
• Outsourcing facilities and compounders serving neonatal intensive-care units.

A competitor would not need to reproduce the NOURESS brand. It would need to match the clinically relevant product characteristics and satisfy FDA requirements for injectable quality, composition, sterility, stability, and labeling.

What method-of-use patents could protect NOURESS?

Method-of-use protection is narrower than product protection. Potential claims could cover:

• Use in premature infants.
• Use in neonates requiring parenteral nutrition.
• Use at a specified amino-acid dose or infusion rate.
• Use with specified glucose, lipid, electrolyte, or trace-element regimens.
• Use in patients with defined renal or hepatic conditions.

These claims would face practical enforcement limits. Pediatric parenteral nutrition is administered under individualized clinical protocols, and hospitals may use multiple amino-acid products interchangeably when clinically appropriate. Method-of-use claims are more valuable when they produce a specific clinical outcome and can be clearly identified in prescribing or reimbursement records.

What manufacturing and IP barriers affect NOURESS?

The most defensible commercial know-how concerns process control rather than chemical composition.

Sterile manufacturing

The manufacturer must control bioburden, endotoxin, particulate matter, aseptic filling, sterilization validation, and container-closure integrity. Amino-acid solutions can create process-specific challenges involving pH, heat exposure, discoloration, degradation products, and interactions with packaging materials.

Container and closure

Container selection is commercially important. A successful product should control:

• Oxygen transmission.
• Light exposure.
• Adsorption or absorption of amino acids.
• Rubber-closure compatibility.
• Extractables and leachables.
• Breakage and handling risk in hospital pharmacies.
• Dose withdrawal accuracy.

Ready-to-use vials can reduce pharmacy compounding steps. Larger bags may reduce unit cost but create different sterility, storage, and wastage considerations.

Supply chain

The product depends on multiple pharmaceutical-grade amino acids rather than one active ingredient. Supply interruption involving a single amino acid can stop finished-product release. Dual sourcing, validated alternate suppliers, and defined impurity specifications are therefore valuable commercial assets.

What excipient opportunities exist for NOURESS?

Preservative-free neonatal presentations

A preservative-free platform is the most defensible baseline. Commercial extensions could include smaller-volume presentations for low-dose neonatal use and packaging that minimizes residual volume and preparation waste.

Ready-to-use parenteral-nutrition components

A ready-to-use amino-acid product can reduce pharmacy labor and manipulation. Opportunities include:

• 50 mL and 100 mL neonatal presentations.
• Larger hospital pharmacy presentations.
• Unit-dose packaging.
• Barcode-enabled labels.
• Dose-volume markings.
• Compatibility-tested transfer devices.

Any new presentation would require product-specific stability, sterility, container-closure, and labeling support.

Higher-concentration products

Higher concentrations can reduce fluid volume in patients with fluid restriction. A 5% or 10% pediatric amino-acid product could compete on fluid management, but it would increase osmolality and could change peripheral-versus-central administration requirements. This is a clinically meaningful differentiation opportunity but carries greater development and labeling risk.

Cysteine and specialized neonatal nutrition

Cysteine supplementation is common in neonatal parenteral nutrition because cysteine availability and stability can be limited in premature infants. A product strategy could include a separately packaged cysteine component or a validated compatible system. A premixed product would face greater stability and compatibility challenges because amino acids, cysteine, electrolytes, glucose, and trace elements can interact during storage.

Reduced-aluminum and impurity-controlled products

A product with tightly controlled aluminum, heavy metals, particulates, and degradation products can compete for neonatal intensive-care contracts. The commercial claim should be supported by release specifications and validated analytical methods rather than broad marketing language.

How does NOURESS compare with TrophAmine and other amino-acid injections?

Factor	NOURESS	TrophAmine and comparable products
Primary market	Neonatal and pediatric nutrition	Neonatal, pediatric, or broader parenteral nutrition
Formulation focus	Pediatric amino-acid injection	Product-specific amino-acid composition
Excipient strategy	Minimal injectable excipients	Generally minimal, product-dependent
Differentiation	Pediatric labeling and supply option	Established institutional use and contracts
Patent moat	Limited	Generally limited for conventional formulations
Main barrier	Sterile manufacturing and regulatory compliance	Scale, contracts, and supply reliability
Expansion path	Presentations, concentration, compatibility data	Portfolio breadth and hospital integration

NOURESS can compete without owning the entire parenteral-nutrition portfolio. Its strongest position is as a reliable pediatric-specific component within hospital nutrition protocols.

What FDA regulatory issues affect NOURESS?

The principal FDA issues are sterile injectable quality and product-specific equivalence. A follow-on applicant must address:

• Active amino-acid identity and concentration.
• Inactive ingredients and pH adjustment.
• Osmolality and physiochemical characteristics.
• Sterility and bacterial endotoxins.
• Particulate matter.
• Stability through labeled storage.
• Container-closure integrity.
• Compatibility after dilution or admixture.
• Labeling for neonatal and pediatric use.
• Aluminum and elemental impurity controls.

FDA drug-shortage conditions can increase the commercial value of a dependable supplier. Hospitals may accept a second source when an incumbent product is unavailable, but durable conversion requires contract pricing, pharmacy validation, and predictable allocation.

What generic launch scenarios exist for NOURESS?

Scenario 1: Direct ANDA competition

A generic manufacturer matches the composition, dosage form, route, concentration, labeling, and performance of NOURESS. This is the most direct erosion scenario if no blocking patent remains.

Scenario 2: 505(b)(2) competition

A company develops a materially different concentration, container, or formulation and relies partly on existing clinical literature. This route could support differentiated products but would require stronger formulation and clinical justification.

Scenario 3: Hospital-compounding substitution

Compounding pharmacies and outsourcing facilities supply amino-acid solutions during shortages or for customized neonatal nutrition. This can pressure demand without creating a traditional generic competitor.

Scenario 4: Portfolio-based competition

A large parenteral-nutrition supplier bundles amino acids with dextrose, lipids, electrolytes, or pharmacy services. Contracting leverage, not patent rights, becomes the primary competitive weapon.

What licensing deals could create value?

Potential licensing transactions would focus on commercial infrastructure rather than molecule ownership. Relevant structures include:

• Regional distribution licenses for pediatric hospitals.
• Co-manufacturing agreements with sterile injectable producers.
• Supply agreements for pharmaceutical-grade amino acids.
• Hospital-group purchasing contracts.
• Licensing of ready-to-use container systems.
• Co-development of higher-concentration or cysteine-compatible products.
• Data-sharing agreements covering admixture stability and neonatal compatibility.

The most valuable partner would provide validated sterile capacity, national hospital access, or a broader parenteral-nutrition portfolio.

What is the revenue exposure and commercial outlook?

Revenue exposure is concentrated in hospital and neonatal-care channels. Demand depends on:

• Birth rates and neonatal intensive-care admissions.
• Use of parenteral nutrition in premature infants.
• Hospital pharmacy staffing.
• Product shortages.
• Group purchasing organization contracts.
• Reimbursement and hospital budget constraints.
• Competitor supply reliability.

NOURESS is unlikely to achieve the market size of a mass-market oral drug. Its value is based on recurring institutional demand, high clinical switching costs during shortages, and the importance of reliable sterile supply. Margin expansion is more likely through packaging, contract positioning, and adjacent products than through premium pricing for the amino-acid ingredients themselves.

Key Takeaways

• NOURESS is a pediatric 3% amino-acid injection for parenteral nutrition.
• Its excipient strategy is appropriately minimal and should remain preservative-free for neonatal use.
• The product has limited conventional patent protection because amino acids and the basic injectable platform are established.
• The principal barriers are sterile manufacturing, stability, container-closure performance, impurity control, and hospital supply reliability.
• The strongest product extensions are smaller unit-dose presentations, higher concentrations for fluid-restricted patients, ready-to-use packaging, and cysteine-compatible neonatal nutrition.
• Biosimilar litigation is not relevant because NOURESS is not a biologic.
• Generic risk is more likely to arise through ANDA or 505(b)(2) competition, hospital compounding, or portfolio-based contracting.
• Commercial value is concentrated in neonatal intensive-care units, pediatric hospitals, hospital pharmacies, and parenteral-nutrition contracts.

FAQs

Does NOURESS contain preservatives?

NOURESS uses a minimal injectable formulation and is positioned for neonatal and pediatric parenteral nutrition. Its commercial formulation strategy favors preservative-free single-dose administration.

Can NOURESS be used in adults?

The product is principally differentiated by neonatal and pediatric use. Adult use depends on the prescribing information, clinical requirements, concentration, route, and institutional parenteral-nutrition protocol.

Is NOURESS a biologic subject to biosimilar competition?

No. NOURESS is an amino-acid injectable drug, not a biologic. Competitive entry would involve generic or 505(b)(2) pathways rather than biosimilar approval.

What is the most attractive new formulation for NOURESS?

A higher-concentration, preservative-free pediatric presentation could address fluid restriction and reduce infusion volume. It would require new stability, osmolality, compatibility, and administration assessments.

Can NOURESS be mixed with dextrose, lipids, electrolytes, or trace elements?

Parenteral-nutrition admixture depends on concentrations, order of mixing, storage conditions, administration route, and validated compatibility data. Mixing should follow the approved labeling and institutional pharmacy procedures.

References

1. U.S. Food and Drug Administration. (n.d.). NOURESS (amino acids) injection: Prescribing information. FDA labeling database.

2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/

3. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

4. U.S. Food and Drug Administration. (2016). Aluminum in large and small volume parenterals used in total parenteral nutrition. FDA guidance and regulatory information.

5. U.S. Pharmacopeia. (2023). USP General Chapter <797>: Pharmaceutical compounding: Sterile preparations. United States Pharmacopeial Convention.